Editorial: β-Adrenergic antagonists for the treatment of clozapine-Induced sinus tachycardia: A retrospective study

Clinical Neuropharmacology

Volumn 32, Issue 5, 2009, Pages 290-292

  Stryjer, Rafael ^a,b   Timinsky, Igor ^a   Reznik, Ilya ^c   Weizman, Abraham ^b,c   Spivak, Baruch ^a,b  

^a NESS ZIONA MENTAL HEALTH CENTER   (Israel)

^b GEHA MENTAL HEALTH CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; CLOZAPINE; PROPRANOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EDITORIAL; FEMALE; HUMAN; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SINUS TACHYCARDIA; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; PATHOPHYSIOLOGY;

ADRENERGIC BETA-ANTAGONISTS; ADULT; CLOZAPINE; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TACHYCARDIA, SINUS; YOUNG ADULT;

EID: 70349795925     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181a620b2     Document Type: Editorial

References (25)

1. Kane J, Honigfeld G, Singer J, et al. The Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenia. Arch Gen Psychiatry 1988;45;789-796.
2. Buchanan RW, Breier A, Kirkpatrick B, et al. Positive and negative symptoms response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 1998;155:751-760.
3. Miller DD. Review and management of clozapine side effects. J Clin Psychiatry 2000;61(suppl 8):14-17.
4. Cohen H, Loewenthal U, Matar M, et al. Association of autonomic dysfunction and clozapine. Heart rate variability and risk for sudden death in patients with schizophrenia on long-term psychotropic medication. Br J Psychiatry 2001;179:167-171.
5. La Grenade L, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med 2001;345:224-225.
6. Coulter DM, Bate A, Meyboom RH, et al. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ 2001;322:1207-1209.
7. Modai I, Hirscmann S, Rava A, et al. Sudden death in patients receiving clozapine treatment:A preliminary investigation. J Clin Psychopharmacol 2000;20:325-327.
8. Novartis Pharmaceuticals. New boxed warning for clozapine for myocarditis (Novartis' document). Pharmacy Newsl Dorothea Dix Hospital. 2002;6(2). Spring.
9. Topol EJ. Textbook of Cardiovascular Medicine. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002.
10. Merrick AF, Odom NJ, Keenan DJ, et al. Comparison of propafenone to atenolol for the prophylaxis of postcardiotomy supraventricular tachyarrhythmias:A prospective trial. Eur J Cardiothorac Surg 1995; 9:146-149.
11. Coxsackie B5 virus infections during 1965:A report to the director of the Public Health Laboratory Service from various laboratories in the United Kingdom. BMJ 1967;4:575-577.
12. Drory Y, Turetz Y, Hiss Y, et al. Sudden unexpected death in persons less than 40 years of age. Am J Cardiol 1991;68:1388-1392.
13. Bristow MR, Ginsburg R, Fowler M, et al. A1- and A2-adrenergic receptor subpopulations in normal and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective A1-receptor downregulation in heart failure. Circ Res 1986;59:297-309.
14. Brodde OE, Schuler S, Kretsch R, et al. Regional distribution of A-adrenoceptors in the human heart: coexistence of functional A1- and A2-adrenoceptors in both atria and ventricles in severe congestive cardiomyopathy. J Cardiovasc Pharmacol 1986;8:1235-1242.
15. Bristow MR. Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol 1993;22(suppl A):61AY71A.
16. Mann DL, Kent RL, Parsons B, et al. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85:790-804.
17. Port JD, Weinberger HD, Bisognano JD, et al. Echocardiographic and histopathological characterization of young and old transgenic mice over-expressing the human Ab1-adrenergic receptor. J Am Coll Cardiol 1998;31(suppl A):177A.
18. Engelhardt S, Hein L, Wiesman F, et al. Progressive hypertrophy and heart failure in A1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A 1999;96:7059-7064.
19. Iwase M, Bishop SP, Uechi M, et al. Adverse effects of chronic endogenous sympathetic drive induced by cardiac Gsa overexpression. Circ Res 1996;78:517-524.
20. D'Angelo DD, Sakatra Y, Lorenz JN, et al. Transgenic Gq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci U S A 1997;94:8121-8126.
21. Rump AF, Theisohn M, Klaus W. The pathophysiology of cocaine cardiotoxicity. Forensic Sci Int 1995;71:103-105.
22. Wilkenfeld C, Cohen M, Lansman SL, et al. Heart transplantation for end-stage cardiomyopathy caused by an occult pheochromocytoma. J Heart Lung Transplant 1992;11(2 pt 1):363-366.
23. Dec GW Jr, Palacios IF, Fallon JT, et al. Active myocarditis in the spectrum of acute dilated cardiomyopathies: clinical features, histologic correlates, and clinical outcome. N Engl J Med 1985; 312:885-890.
24. Vignola PA, Aonuma K, Swaye PS, et al. Lymphocytic myocarditis presenting as unexplained ventricular arrhythmias: diagnosis with endomyocardial biopsy and response to immunosuppression. J Am Coll Cardiol 1984;4:812-819.
25. Dec GW Jr, Waldman H, Southern J, et al. Viral myocarditis mimicking acute myocardial infarction. J Am Cardiol 1992;20:85-89.